Here is the design of a clinical trial:

Official Title: Oral-only Antibiotics for Bone and Joint Infections in Children - A Nationwide Randomized Controlled Trial

Included conditions:
- Osteomyelitis
- Septic Arthritis
- Bone Infection
- Joint Infection
- Bone and Joint Infection

Study Armgroups:
- {'label': 'Experimental', 'type': 'ACTIVE_COMPARATOR', 'description': '\\< 5 years: High-dose oral co-amoxiclav (1:8) 33 mg amoxicillin/kg/dose (max. 1 g) three-times daily (TDS) until clinical and paraclinical improvement (min. 3 days) followed by oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).\n\n=/\\> 5 years: High-dose oral dicloxacillin 50 mg/kg/dose (max. 2 g) four-times daily (QID) until clinical and paraclinical improvement (min. 3 days) followed by oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).\n\nTreatment will be adjusted according to microbiological findings.', 'interventionNames': ['Drug: Oral co-amoxiclav or oral dicloxacillin only']}
- {'label': 'Standard', 'type': 'ACTIVE_COMPARATOR', 'description': 'IV ceftriaxon 100 mg/kg/dose (max. 4 g) once daily (QD) (all ages) until clinical and paraclinical improvement (min. 3 days) followed by:\n\n\\< 5 years: Oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).\n\n\\>/= 5 years: Oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).\n\nTreatment will be adjusted according to microbiological findings.', 'interventionNames': ['Drug: IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin']}

Interventions:
- {'type': 'DRUG', 'name': 'Oral co-amoxiclav or oral dicloxacillin only', 'description': 'High dose oral treatment followed by standard dose oral treatment', 'armGroupLabels': ['Experimental']}
- {'type': 'DRUG', 'name': 'IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin', 'description': 'IV treatment followed by standard dose oral treatment', 'armGroupLabels': ['Standard']}

Primary Outcomes:
- {'measure': 'Sequelae at 6 months', 'description': 'Proportion of children with sequelae 6 months after initiation of treatment defined as abnormal mobility or function of the affected joint/bone. Evaluated by blinded clinical examination by a qualified pediatrician and/or pediatric orthopedic surgeon.', 'timeFrame': '6 months'}

Please estimate the sample size based on the assumption: 
One-sided significance level (alpha) of 2.5%, power of 90%, and a 10% rate of drop-out
Sample size and power calculation
        Outcomes will be compared by a non-inferiority assumption with an inferiority margin of 5% and an expected treatment success of 99% in both groups. With a one-sided significance level (alpha) of 2.5% and accounting for a 10% rate of drop-out, a sample size of 180 children in the principal stratum, 90 children in each group, will provide a power of 90% to detect non-inferiority.